FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079783035> ?p ?o ?g. }

• W2079783035 endingPage "48" @default.
• W2079783035 startingPage "37" @default.
• W2079783035 abstract "Prostatitis is a collection of signs and symptoms that occur as a result of inflammation or swelling of the prostate gland. There are many different causes for prostatitis, including infection; occasionally no clear etiology for the inflammation is found. Effective treatment often depends on identification of the cause, but a microbiologic organism is not always detectable, especially in cases of chronic prostatitis. The aim of this article was to review identification and treatment options for prostatitis, including pharmacologic and nonpharmacologic interventions. Relevant information was identified through a search of MEDLINE (1966–June 2010), International Pharmaceutical Abstracts (1970–June 2010), and EMBASE (1947–June 2010). Randomized, controlled trials that examined prostate cancer, benign prostatic hypertrophy, or procedures related to the prostate (ie, biopsies) were excluded. A working classification system for prostatitis was developed in 1999, but there are few randomized controlled trials that distinguish between the various treatment options. Bacterial prostatitis can be acute or chronic but always requires some degree of antimicrobial therapy. Pharmacologic features of fluoroquinolones make them the preferred agents for most patients. These antibiotics can become trapped in a chronically inflamed prostate due to pH differences between prostatic tissue and serum. Many fluoroquinolones have penetration ratios (prostate level:serum level) of up to 4:1. A study in European men (N = 117) who received levofloxacin 500 mg/d with a diagnosis of chronic bacterial prostatitis demonstrated clinical success rates of 92% (95% CI 84.8%–96.5%), 77.4% (95% CI, 68.2–84.9%), 66.0% (95% CI, 56.2%–75.0%), and 61.9% (95% CI, 51.9%–71.2%) at 5–12 days, 1 month, 3 months, and 6 months after treatment. Additionally, there have been numerous randomized, placebo-controlled trials in patients with chronic prostatitis that have studied α-blockers, steroid inhibitors, anti-inflammatory agents, and bioflavonoids. Treatment responses to α-blockers appear to be greater with longer durations of therapy in α-blocker–naïve patients (National Institutes of Health-Chronic Prostatitis Symptom Index [NIH-CPSI] score reduction of at least 3.6 points after 6 weeks of tamsulosin therapy [P = 0.04] and up to 14.3 and 9.9 point NIH-CPSI score reductions with 14 weeks of terazosin and 24 weeks of alfuzosin therapy, respectively [P = 0.01 for both]). Combination therapy with an α-blocker, an anti-inflammatory, and a muscle relaxant does not appear to offer significant advantages over monotherapy (12.7 vs 12.4 point reduction in NIH-CPSI scores) and a stepwise approach to therapy involving antibiotics followed by bioflavonoids and then α-blockers appears to effectively reduce symptoms for up to 1 year in patients with chronic prostatitis (mean NIH-CPSI point reduction of 9.5 points compared with baseline, P < 0.0001). Patients who have had multiple unsuccessful treatment regimens may benefit from direct stimulation of the pelvic muscles through electromagnetic or electroacupuncture therapy. Prostatitis can resemble various other medical conditions but proper classification and an understanding of the pharmacologic features and expectations of the medications used to treat it can help identify effective treatment strategies. Fluoroquinolones are the preferred agents for treating bacterial causes of prostatitis and have demonstrated efficacy in some cases of chronic prostatitis when an organism has not been identified. However, the use of agents with anti-inflammatory or antiadrenergic properties may be necessary in combination with or after trying antimicrobial agents." @default.
• W2079783035 created "2016-06-24" @default.
• W2079783035 creator A5016123667 @default.
• W2079783035 creator A5049069749 @default.
• W2079783035 date "2011-02-01" @default.
• W2079783035 modified "2023-10-16" @default.
• W2079783035 title "Identification, Pharmacologic Considerations, and Management of Prostatitis" @default.
• W2079783035 cites W1572187112 @default.
• W2079783035 cites W1965625101 @default.
• W2079783035 cites W1966857852 @default.
• W2079783035 cites W1967438689 @default.
• W2079783035 cites W1968481120 @default.
• W2079783035 cites W1968726185 @default.
• W2079783035 cites W1969159589 @default.
• W2079783035 cites W1969897346 @default.
• W2079783035 cites W1973214716 @default.
• W2079783035 cites W1973892744 @default.
• W2079783035 cites W1979570571 @default.
• W2079783035 cites W1993949433 @default.
• W2079783035 cites W1994459308 @default.
• W2079783035 cites W1997517088 @default.
• W2079783035 cites W2002743779 @default.
• W2079783035 cites W2010223298 @default.
• W2079783035 cites W2013093771 @default.
• W2079783035 cites W2027766463 @default.
• W2079783035 cites W2032492978 @default.
• W2079783035 cites W2033542880 @default.
• W2079783035 cites W2037558979 @default.
• W2079783035 cites W2037718510 @default.
• W2079783035 cites W2038179116 @default.
• W2079783035 cites W2039692590 @default.
• W2079783035 cites W2039870059 @default.
• W2079783035 cites W2046425627 @default.
• W2079783035 cites W2047805225 @default.
• W2079783035 cites W2059380428 @default.
• W2079783035 cites W2060723378 @default.
• W2079783035 cites W2061767214 @default.
• W2079783035 cites W2064528345 @default.
• W2079783035 cites W2067444199 @default.
• W2079783035 cites W2068324474 @default.
• W2079783035 cites W2072824380 @default.
• W2079783035 cites W2072850041 @default.
• W2079783035 cites W2075136705 @default.
• W2079783035 cites W2076617109 @default.
• W2079783035 cites W2078564462 @default.
• W2079783035 cites W2086251123 @default.
• W2079783035 cites W2089738403 @default.
• W2079783035 cites W2093384534 @default.
• W2079783035 cites W2093424875 @default.
• W2079783035 cites W2097199316 @default.
• W2079783035 cites W2103646177 @default.
• W2079783035 cites W2106179838 @default.
• W2079783035 cites W2111553467 @default.
• W2079783035 cites W2120069974 @default.
• W2079783035 cites W2135578992 @default.
• W2079783035 cites W2136725579 @default.
• W2079783035 cites W2140009150 @default.
• W2079783035 cites W2149112361 @default.
• W2079783035 cites W2149820490 @default.
• W2079783035 cites W2152331728 @default.
• W2079783035 cites W2153571340 @default.
• W2079783035 cites W2167757606 @default.
• W2079783035 cites W2168275540 @default.
• W2079783035 cites W3022579983 @default.
• W2079783035 cites W4252866586 @default.
• W2079783035 cites W4317676495 @default.
• W2079783035 cites W4365787290 @default.
• W2079783035 doi "https://doi.org/10.1016/j.amjopharm.2011.02.005" @default.
• W2079783035 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21459307" @default.
• W2079783035 hasPublicationYear "2011" @default.
• W2079783035 type Work @default.
• W2079783035 sameAs 2079783035 @default.
• W2079783035 citedByCount "12" @default.
• W2079783035 countsByYear W20797830352012 @default.
• W2079783035 countsByYear W20797830352013 @default.
• W2079783035 countsByYear W20797830352014 @default.
• W2079783035 countsByYear W20797830352015 @default.
• W2079783035 countsByYear W20797830352016 @default.
• W2079783035 countsByYear W20797830352018 @default.
• W2079783035 countsByYear W20797830352021 @default.
• W2079783035 crossrefType "journal-article" @default.
• W2079783035 hasAuthorship W2079783035A5016123667 @default.
• W2079783035 hasAuthorship W2079783035A5049069749 @default.
• W2079783035 hasConcept C121608353 @default.
• W2079783035 hasConcept C126322002 @default.
• W2079783035 hasConcept C126894567 @default.
• W2079783035 hasConcept C137627325 @default.
• W2079783035 hasConcept C168563851 @default.
• W2079783035 hasConcept C2776235491 @default.
• W2079783035 hasConcept C2779478474 @default.
• W2079783035 hasConcept C2779529836 @default.
• W2079783035 hasConcept C2780192828 @default.
• W2079783035 hasConcept C2780524745 @default.
• W2079783035 hasConcept C2780546585 @default.
• W2079783035 hasConcept C2781276175 @default.
• W2079783035 hasConcept C501593827 @default.
• W2079783035 hasConcept C71924100 @default.
• W2079783035 hasConcept C86803240 @default.

• next